Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib + Intensive Chemotherapy in AML/MDS
NCT02198482Phase 2Terminated
- Sponsor
- Ulm University
- Start
- Feb 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of volasertib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Ulm University. Started Feb 2016; status: terminated.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02198482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198482.